From the DHHS OIG website'sadvisory opinion archive which OIG indicated that it might take enforcement action against an activity proposed by a pharmaceutical or medical device company.

If corporate compliance for the company that requested the advisory opinion. In that capacity What are the OIG's concerns about the activities proposed by a company?

What alternative strategies a company can use that would be more likely to meet with the OIG's approval?